Opinion|Videos|December 9, 2024
Closing Thoughts and Unmet Needs in Glioma Treatment
Author(s)Vinay K. Puduvalli, MD
Panelists discuss how unmet needs in glioma treatment persist despite recent advances, highlighting key areas for future research and development to improve outcomes and quality of life for patients with gliomas.
Advertisement
Episodes in this series
Advertisement
Related to this article
Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable cholangiocarcinoma.
An analysis of the BENEFIT trial supports isatuximab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care in transplant-ineligible NDMM.
C. Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible framework in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
A patient-reported outcomes analysis from the phase 3 IRAKLIA trial showed higher satisfaction with subcutaneous isatuximab via on-body injector.
The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed/refractory multiple myeloma.
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acting on a HER2 Result and Navigating Access to Therapy
2
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
3
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
4
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
5